Search Results
Your search for can matches 13380 pages
Showing 1151 - 1200There’s an App for That: Digital Health Solutions for Treating Insomnia in Cancer Survivors
Guest Editor’s Note: Insomnia is common in patients with cancer and cancer survivors, and it has significant negative consequences. Cognitive behavior therapy for insomnia (CBT-I) is an effective approach for managing insomnia but is not easily available to many patients. In this installment of The ...
Instinct and Perseverance Helped Save Me From Two Cancers
My intuition about my health has served me well over the past 10 years, possibly even saving my life from two serious cancers. In 2013, I was diagnosed with follicular lymphoma. I believe that my awareness of changes in my body led to its early discovery. One evening, after exercising at the gym...
Vivek Subbiah, MD, Joins SCRI to Advance Early-Phase Clinical Research
Sarah Cannon Research Institute (SCRI) recently announced that Vivek Subbiah, MD, has joined the organization as Chief, Early-Phase Drug Development. In his role, Dr. Subbiah will oversee SCRI’s nine drug development units and lead the expansion of early-phase capabilities and programs across the...
Radiation Exposure From Medical Imaging in Pediatric Patients With Down Syndrome
Pediatric patients with Down syndrome may undergo almost 10 times as many medical imaging examinations as other pediatric patients, potentially exposing them to more ionizing radiation, according to a recent study published by Marlow et al in PLOS ONE. Background Ionizing radiation is present in...
High-Grade Serous Ovarian Cancer: Impact of Multimodal Screening on Survival
In an analysis of the UKCTOCS study reported in The Lancet Oncology, Menon et al found that patients with high-grade serous tubo-ovarian cancer detected on multimodal screening may have a survival benefit over those whose disease was diagnosed without screening. The investigator stated, “In...
Enhanced Recovery Program May Be Effective at Reducing Opioid Use After Pancreatic Cancer Surgery
Improving hospital care pathways may help reduce inpatient opioid use by 50% and cut the median opioid prescription volumes at discharge to zero in patients undergoing pancreatic cancer surgery, according to a recent study published by Boyev et al in JAMA Surgery. The new findings could help reduce ...
SNMMI Provides New Consensus Statement on LuPSMA Therapy
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has provided standardized guidance on the selection and management of patients receiving lutetium-177–labeled PSMA-617 (LuPSMA) radionuclide therapy for metastatic castration-resistant prostate cancer, according to a new consensus...
Is Cardiovascular Disease Linked to Increased Risk of Cancer?
In a retrospective cohort study reported in JACC: CardioOncology, Bell et al found individuals with a diagnosis of cardiovascular disease were more likely to have a subsequent cancer diagnosis than individuals with no cardiovascular disease diagnosis. Risk was elevated among persons with...
Phase III Trial Reports Chemoimmunotherapy Is Superior to Chemotherapy Alone in Malignant Pleural Mesothelioma
Patients with malignant pleural mesothelioma who were treated with a chemoimmunotherapy regimen containing the immune checkpoint inhibitor pembrolizumab experienced significantly improved overall survival compared with those treated with chemotherapy alone, with acceptable tolerability, according...
Can AI Assessment of Screening Mammograms Offer Similar Accuracy to Human Readers?
A commercially available artificial intelligence (AI) algorithm may perform comparably to human readers at assessing screening mammograms, according to a recent study published by Chen et al in Radiology. False-positive interpretations on screening mammograms can result in women without cancer...
23andMe Granted FDA 510(k) Clearance to Report Additional BRCA Variants
23andMe has announced that the company has received a U.S. Food and Drug Administration (FDA) 510(k) clearance to expand its existing BRCA1/BRCA2 (Selected Variants) Genetic Health Risk Report. The clearance allows 23andMe to report an additional 41 variants in the BRCA1 and BRCA2 genes known to be ...
Statins May Be Linked to Lower Risk of Colorectal Cancer in Patients With Ulcerative Colitis
Cholesterol-lowering statins may reduce colorectal cancer incidence and mortality in patients with ulcerative colitis, according to a recent study published by Sun et al in eClinicalMedicine. The findings also suggested that statin use may be associated with a lower risk of all-cause mortality in...
Strategies to Predict Immunotherapy Benefit Among Patients With Advanced Colorectal Cancer
Researchers have identified new strategies to help physicians predict which patients with advanced colorectal cancer may benefit from immunotherapy, according to a recent study published by Saberzadeh-Ardestani et al in Clinical Cancer Research. The findings demonstrate the potential of using...
New Data on a Response Biomarker for Dovitinib in Patients With RCC
A new report published by Knudsen et al in PLOS ONE focused on the clinical validation of a drug response predictor (DRP) biomarker algorithm for dovitinib, a receptor tyrosine kinase inhibitor of VEGFR1–3, PDGFR, FGFR1/3, c-KIT, FLT3, and topoisomerase 1 and 2. Data showed that the DRP-dovitinib...
Improving Nutrition Guidance May Optimize Fertility Treatments for Female Cancer Survivors
Researchers have identified potential strategies to promote healthy dietary habits in female cancer survivors with fertility challenges, according to a recent study published by Klobodu et al in Integrative Cancer Therapies. Background Cancer may increase the risk of infertility in young female...
Time Gaps May Be Critical Parameters When Sparing Skin During FLASH Radiation Therapy
Researchers have demonstrated that, in preclinical models, multiple beams and intervals in delivery during FLASH radiation therapy may compromise the skin-sparing effects of the technique, according to a novel study published by Mascia et al in the International Journal of Radiation Oncology •...
How Is Administrative Payment Burden Associated With Cost-Related Delays in Cancer Care?
Research shows that the United States’ health-care delivery and financing system is so complex that streamlining administrative costs alone could reduce total health-care spending by 15%. In addition, health insurance payment and medical billing processes are time-consuming and expensive for both...
Optimizing Tobacco Cessation Treatment With Lung Cancer Screenings
The Program for Lung Cancer Screening and Tobacco Cessation trial tested different adaptive interventions based on the evidence-based Tobacco Longitudinal Care (TLC) program, in part to learn how best to incorporate TLC into annual lung cancer screening as a smoking cessation standard. The findings ...
How Guideline-Concordant Are Cancer Treatment Recommendations From ChatGPT?
Researchers have found that about one-third of treatment recommendations from the artificial intelligence (AI) model ChatGPT 3.5 were nonconcordant with the NCCN Clinical Practice Guidelines in Oncology® (NCCN Guidelines®), according to a recent study published by Chen et al in JAMA Oncology. The...
Rural Patients With Cancer: Receipt of Surgical Care at High- vs Low-Volume Hospitals
Patients with cancer who live in rural Pennsylvania counties appear to know that they may have better outcomes if they receive their cancer surgery at a hospital that performs a high volume of those procedures—but many still opt for lower-volume hospitals closer to home when their cancer is likely...
Short-Term Use of Immunosuppressants May Not Be Linked to Increased Cancer Risk in Patients With Ocular Inflammatory Diseases
Short-term use of immunosuppressants in patients with ocular inflammatory disease may not be associated with an increased risk of developing cancer, according to a recent study published by Buchanich et al in BMJ Oncology. Background The Systemic Immunosuppressive Therapy for Eye Diseases (SITE)...
Cardiorespiratory Fitness in Youth May Be Associated With a Lower Risk of Nine Cancer Types
Partaking in cardiorespiratory fitness in youth may be associated with up to a 40% lower risk of developing nine cancer types later in life, according to a recent study published by Onerup et al in the British Journal of Sports Medicine. Background Cardiorespiratory fitness—including sustained...
The Future Priorities of the National Cancer Institute
Fifty-two years ago, President Richard Nixon signed the National Cancer Act of 1971 into law, which established the National Cancer Institute (NCI) in its current form. At the time, the budget was $1.6 billion. Today, it is $7.8 billion, $4.5 billion less than the amount needed to keep up with...
Novel Targeted Therapy Combination May Be an Effective First-Line Option for Gastric or Gastroesophageal Junction Adenocarcinoma
Researchers have found that the novel targeted therapy zolbetuximab in combination with a standard chemotherapy may extend survival in patients with advanced gastric or gastroesophageal junction adenocarcinoma and overexpression of the claudin-18 isoform 2 protein (CLDN18.2), according to a novel...
Crystal S. Denlinger, MD, FACP, Named New Chief Executive Officer of NCCN
On August 23, 2023, the National Comprehensive Cancer Network® (NCCN) announced Crystal S. Denlinger, MD, FACP, as incoming Chief Executive Officer (CEO). Dr. Denlinger, who is currently Senior Vice President and Chief Scientific Officer of NCCN, will lead the global guidelines organization...
Bariatric Surgery and Cancer Incidence and Mortality for Patients With Severe Obesity
Investigators have demonstrated that bariatric surgery may be associated with a lower incidence of all-cancer and obesity-related cancer among female patients, according to a recent study published by Adams et al in Obesity. The new findings also suggested cancer mortality was significantly reduced ...
More on the Complexity of Prior Authorization
We read with interest the recent commentary by S. Monica Soni, MD, and Andrew A. Hertler, MD, FACP, on prior authorization (June 10, 2023, issue of The ASCO Post). The nuances of prior authorization in our health-care landscape are both complex and consequential. Conceived as a safeguard against...
How the Cancer Moonshot Aims to Improve the Quality of Life for Adolescent and Young Adult Cancer Survivors
Several recent studies have shown an increasingly disturbing trend: the incidence of early-onset cancers—those diagnosed in individuals younger than age 50—is on the rise, and not just in the United States but globally as well. Worldwide, in 2019, there were a reported 1.19 million new cases of...
Rapid Guideline Update Offers Key Evidence-Based Recommendations for Stage III NSCLC Management
A new ASCO guideline rapid update provides updated recommendations for the management of stage III non–small cell lung cancer (NSCLC). These updated recommendations made by the ASCO expert panel cover treatment options for patients with resected disease and specific genetic mutations as well as...
Unraveling the Mechanisms Behind the Antichemotherapy Effects of ABCG2 Proteins
Researchers may have discovered how to prevent the cellular-cleaning protein ABCG2 from removing chemotherapeutics from tumor cells, according to a recent study published by Gose et al in Nature Communications. These research findings may improve future cancer therapeutics. Background Most new...
Are All Benzodiazepines Created Equal in Terms of Survival in Patients With Pancreatic Cancer?
Patients with pancreatic cancer who were treated with the benzodiazepine lorazepam had shorter progression-free survival periods than patients who were not, according to study results published by Cornwell et al in Clinical Cancer Research. In contrast, patients who were treated with the...
Researchers May Have Identified Several New Breast Cancer Susceptibility Genes
Researchers have identified genes that may be associated with breast cancer and could eventually be included in tests to identify high-risk patients, according to a recent study published by Wilcox et al in Nature Genetics. Background Currently, genetic tests for breast cancer consider a few genes...
Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease
Rami S. Komrokji, MD, of Moffitt Cancer Center, discusses an assessment of new classifications for myeloid neoplasms and the ongoing efforts to harmonize these classifications, so researchers can better understand risk, outcomes, and survival among patients with genetically distinct types of the...
Chemotherapy Shortage Impacts Patients, Physicians, Costs, and Clinical Trials
Grim, grimmer, and grinding are among the terms reported in the press to describe the current chemotherapy shortage.1,2 And, “it is not going away,” Mark J. Ratain, MD, FASCO, Chief Hospital Pharmacologist, University of Chicago Medicine, told The ASCO Post. “This is a progressive problem like...
Ipilimumab Plus Nivolumab May Improve Outcomes in Patients With Refractory Metastatic Melanoma, Study Suggests
Researchers have discovered that ipilimumab in combination with nivolumab may be an effective second-line therapy in patients with PD-1 blockade–refractory metastatic melanoma, according to a recent study published by VanderWalde et al in Nature Medicine. These findings demonstrated the combination ...
Therapeutic Implications of DNA Repair Discoveries in Patients With Homologous Recombination Deficiencies
Long-molecule scars may help identify patients with BRCA1- and BRCA2-deficient cancer types, according to a recent study published by Setton et al in Nature. Background Once DNA is damaged by toxins, radiation, or normal cell division, human cells must continually fix DNA breaks to survive. When...
Medicaid Expansion and Participation in Cancer Clinical Trials Among Patients Insured by Medicaid
Investigators may have uncovered the impact of the 2014 and 2015 Medicaid expansion on cancer clinical trial participation, according to a recent study published by Unger et al in JAMA Oncology. The new findings suggested that Medicaid expansion under the Patient Protection and Affordable Care Act...
Do MDS Diagnoses Require Second Opinions?
Investigators have identified a need for strong coordination between clinicians and skilled pathologists to ensure accurate, timely diagnosis of myelodysplastic syndromes (MDS). The study findings were recently published by Gorak et al in Blood Advances. Background MDS—a collection of chronic...
Four Novel Biomarkers May Help Detect Black Patients at Risk of Advanced Prostate Cancer
Researchers have identified a cell metabolism process found in male patients with West African ancestry who have diabetes and metastatic prostate cancer that could potentially lead to improved testing and treatments for Black patients with both diseases. The findings by Shuck et al were presented...
Diagnosing Early-Stage Bladder Cancer in Patients With Hematuria: Novel mePENK Test
Researchers have found that the new PENK methylation (mePENK) test could potentially pave the way for a breakthrough in early bladder cancer detection in patients with hematuria, according to a novel study published by Oh et al in The Journal of Molecular Diagnostics. The findings could reduce the...
PSMA PET/CT Imaging May Eliminate the Need for Preimaging Biopsy in Older Patients Undergoing Screening for Prostate Cancer
Prostate-specific membrane antigen positron-emission tomography/computed tomography (PSMA PET/CT) imaging may help physicians diagnose advanced disease and select the appropriate therapeutic interventions in patients aged 80 years or older with suspected prostate cancer, according to a recent study ...
Expert Point of View: Sumanta K. Pal, MD, FASCO
“Hats off to the investigators for the first comparison of triplet to doublet in advanced renal cell carcinoma. This is also the first results using a contemporary control group. The study met its primary endpoint,” said Sumanta K. Pal, MD, FASCO, Co-Director of the Kidney Cancer Program, City of...
COSMIC-313: Triplet Therapy Is Active in Renal Cell Carcinoma, but Toxicities Pose a Challenge
The addition of cabozantinib to nivolumab plus ipilimumab prolonged progression-free survival in untreated intermediate-risk patients with advanced renal cell carcinoma (RCC), according to the first results of the phase III COSMIC-313 trial. These findings were presented as a Presidential Symposium ...
Extended Follow-up Supports First-Line Use of Nivolumab Plus Cabozantinib in Advanced Renal Cell Carcinoma
The 3-year follow-up of the phase III CheckMate 9ER trial demonstrates superior outcomes with the combination of nivolumab plus cabozantinib vs the former standard-of-care sunitinib as first-line treatment of advanced or metastatic renal cell carcinoma.1 These benefits were achieved with the...
Genitourinary Oncology 2023 Almanac
It is an exciting time in the development of new treatments for urologic cancers. There have been a number of major changes both in advanced disease and in the perioperative setting over the past year. Urothelial and Bladder Cancers In urothelial cancer, at last, we have randomized data supporting...
Expert Point of View: Ajay K. Nooka, MD, MPH
Insights on findings from the phase II MonumenTAL-1 trial1 were offered by Ajay K. Nooka, MD, MPH, Professor in the Department of Hematology and Medical Oncology, and Medical Director of the Winship Data and Technology Applications Shared Resource, Winship Cancer Institute, Emory University School ...
Study Shows Activity of Talquetamab in Highly Refractory Multiple Myeloma
In the phase I/II MonumenTAL-1 trial, the novel bispecific antibody talquetamab produced responses in more than 70% of heavily pretreated patients with multiple myeloma.1 Of note, the safety profile confirmed results of the phase I portion of the study (recently published in TheNew England Journal...
Expert Point of View: Urvi A. Shah, MD
Urvi A. Shah, MD, Assistant Attending at Memorial Sloan Kettering Cancer Center and Assistant Professor at Weill Cornell Medicine, New York, moderated the session where the MagnetisMM trial updates1,2 were reported and was interviewed by The ASCO Post. Elranatamab vs Teclistamab Dr. Shah noted...
Ruxolitinib Demonstrates Clinical Activity in a Phase II Trial of Chronic Myelomonocytic Leukemia
In a phase II trial, treatment with the JAK2 inhibitor ruxolitinib resulted in clinical activity in two-thirds of patients with chronic myelomonocytic leukemia (CMML) with splenomegaly or an otherwise high disease symptom burden. The magnitude of symptomatic benefit was similar to that observed in...
Is Zanubrutinib Poised to Become a New Standard of Care in Relapsed or Refractory CLL and SLL?
The next-generation Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib demonstrated superior progression-free survival compared with ibrutinib, with an improved cardiac safety profile, in the first head-to-head comparison between these two BTK inhibitors in relapsed or refractory chronic...
